Cyclophilin A: Potential functions and therapeutic target for human cancer

Medical Science Monitor

Volumn 15, Issue 11, 2009, Pages

  Obchoei, Sumalee ^a,b   Wongkhan, Sopit ^b   Wongkham, Chaisiri ^b   Li, Min ^a   Yao, Qizhi ^a   Chen, Changyi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Apoptosis; Cancer; CD147; Cell proliferation; Cyclophilin A; Cyclosporin A; Drug resistance; Tumor invasion; Tumor migration

Indexed keywords

CD147 ANTIGEN; CISPLATIN; CYCLOPHILIN A; CYCLOSPORIN A; CYCLOSPORIN A [3 N METHYL DEXTRO ALANINE 4 N ETHYLVALINE]; DOXORUBICIN; PACLITAXEL; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VINCRISTINE;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER THERAPY; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; DISEASE ASSOCIATION; DRUG TARGETING; ENDOMETRIUM CARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MOLECULAR MECHANICS; NEOPLASM; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR; TUMOR GROWTH;

CYCLOPHILIN A; HUMANS; NEOPLASMS;

EID: 71649105843     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (161)

1. Handschumacher RE, Harding MW, Rice J et al: Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science, 1984; 226: 544-547 (Pubitemid 14018525)
2. Colgan J, Asmal M, Yu BLuban J: Cyclophilin A-deficient mice are resistant to immunosuppression by cyclosporine. J Immunol, 2005; 174: 6030-6038 (Pubitemid 40663790)
3. Dornan J, Taylor PWalkinshaw MD: Structures of immunophilins and their ligand complexes. Curr Top Med Chem, 2003; 3: 1392-1409
4. Wang P, Heitman J: The cyclophilins. Genome Biol, 2005; 6: 226
5. Ryffel B, Woerly G, Greiner B et al: Distribution of the cyclosporine binding protein cyclophilin in human tissues. Immunology, 1991; 72: 399-404
6. Willenbrink W, Halaschek J, Schuffenhauer S et al: Cyclophilin A, the major intracellular receptor for the immunosuppressant cyclosporin A, maps to chromosome 7p11.2-p13: four pseudogenes map to chromosomes 3, 10, 14, and 18. Genomics, 1995; 28: 101-104
7. Bachinger HP: The influence of peptidyl-prolyl cis-trans isomerase on the in vitro folding of type III collagen. J Biol Chem, 1987; 262: 17144-17148
8. Fischer G, Bang H: The refolding of urea-denatured ribonuclease A is catalyzed by peptidyl-prolyl cis-trans isomerase. Biochim Biophys Acta, 1985; 828: 39-42
9. Lang K, Schmid FX, Fischer G: Catalysis of protein folding by prolyl isomerase. Nature, 1987; 329: 268-270 (Pubitemid 17128975)
10. Ou WB, Luo W, Park YD, Zhou HM: Chaperone-like activity of peptidyl- prolyl cis-trans isomerase during creatine kinase refolding. Protein Sci, 2001; 10: 2346-2353 (Pubitemid 32988650)
11. Colgan J, Asmal M, Neagu M et al: Cyclophilin A regulates TCR signal strength in CD4+ T cells via a proline-directed conformational switch in Itk. Immunity, 2004; 21: 189-201 (Pubitemid 39094049)
12. Galat A: Peptidylproline cis-trans-isomerases: immunophilins. Eur J Biochem, 1993; 216: 689-707
13. Kofron JL, Kuzmic P, Kishore V et al: Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry, 1991; 30: 6127-6134
14. Arora K, Gwinn WM, Bower MA et al: Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol, 2005; 175: 517-522 (Pubitemid 40884357)
15. Boulos S, Meloni BP, Arthur PG et al: Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol Dis, 2007; 25: 54-64 (Pubitemid 44765217)
16. Jin ZG, Lungu AO, Xie L et al: Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol, 2004; 24: 1186-1191 (Pubitemid 38880006)
17. Kim SH, Lessner SM, Sakurai Y, Galis ZS: Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. Am J Pathol, 2004; 164: 1567-1574 (Pubitemid 38529759)
18. Jin ZG, Berk BC: SOXF: redox mediators of vascular smooth muscle cell growth. Heart, 2004; 90: 488-490 (Pubitemid 38530158)
19. Seko Y, Fujimura T, Taka H, Mineki R et al: Hypoxia followed by reoxygenation induces secretion of cyclophilin A from cultured rat cardiac myocytes. Biochem Biophys Res Commun, 2004; 317: 162-168 (Pubitemid 38401978)
20. Sherry B, Yarlett N, Strupp A, Cerami A: Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci USA, 1992; 89: 3511-3515
21. Yurchenko V, Zybarth G, O'Connor M et al: Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem, 2002; 277: 22959-22965 (Pubitemid 34967280)
22. Yang H, Li M, Chai H et al: Effects of cyclophilin A on cell proliferation and gene expressions in human vascular smooth muscle cells and endothelial cells. J Surg Res, 2005; 123: 312-319 (Pubitemid 40186914)
23. Kim H, Kim WJ, Jeon ST et al: Cyclophilin A may contribute to the in- flammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin Immunol, 2005; 116: 217-224 (Pubitemid 41112725)
24. Suzuki J, Jin ZG, Meoli DF et al: Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res, 2006; 98: 811-817 (Pubitemid 43755265)
25. Jin ZG, Melaragno MG, Liao DF et al: Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res, 2000; 87: 789-796
26. Liao DF, Jin ZG, Baas AS et al: Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem, 2000; 275: 189-196
27. Billich A, Winkler G, Aschauer H et al: Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. J Exp Med, 1997; 185: 975-980 (Pubitemid 27119882)
28. Andersen H, Jensen ON, Eriksen EF: A proteome study of secreted prostatic factors affecting osteoblastic activity: identification and chara terisation of cyclophilin A. Eur J Cancer, 2003; 39: 989-995 (Pubitemid 36428632)
29. Peng H, Vijayakumar S, Schiene-Fischer C et al: Secreted Cyclophilin A, a Peptidylprolyl cis-trans Isomerase, Mediates Matrix Assembly of Hensin, a Protein Implicated in Epithelial Differentiation. J Biol Chem, 2009; 284: 6465-6475
30. Endrich MM, Gehring H: The V3 loop of human immunodeficiency virus type-1 envelope protein is a high-affinity ligand for immunophilins present in human blood. Eur J Biochem, 1998; 252: 441-446
31. Tegeder I, Schumacher A, John S et al: Elevated serum cyclophilin levels in patients with severe sepsis. J Clin Immunol, 1997; 17: 380-386 (Pubitemid 27431977)
32. Pushkarsky T, Zybarth G, Dubrovsky L et al: CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. Proc Natl Acad Sci USA, 2001; 98: 6360-6365 (Pubitemid 32488243)
33. Gwinn WM, Damsker JM, Falahati R et al: Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention. J Immunol, 2006; 177: 4870-4879 (Pubitemid 44469823)
34. Agarwal PK: Cis/trans isomerization in HIV-1 capsid protein catalyzed by cyclophilin A: insights from computational and theoretical studies. Proteins, 2004; 56: 449-463
35. Franke EK, Yuan HE, Luban J: Specific incorporation of cyclophilin A into HIV-1 virions. Nature, 1994; 372: 359-362 (Pubitemid 24363437)
36. Franke EK, Luban J: Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gagcyclophilin A interaction. Virology, 1996; 222: 279-282
37. Pushkarsky T, Yurchenko V, Laborico A, Bukrinsky M: CD147 stimulates HIV-1 infection in a signal-independent fashion. Biochem Biophys Res Commun, 2007; 363: 495-499 (Pubitemid 47513657)
38. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW: Serial analysis of gene expression. Science, 1995; 270: 484-487
39. Lal A, Lash AE, Altschul SF et al: A public database for gene expression in human cancers. Cancer Res, 1999; 59: 5403-5407 (Pubitemid 29526444)
40. Siu IM, Lal A, Riggins GJ: A database for regional gene expression in the human brain. Brain Res Gene Expr Patterns, 2001; 1: 33-38 (Pubitemid 33634193)
41. Boon K, Eberhart CG, Riggins GJ: Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res, 2005; 65: 703-707 (Pubitemid 40216425)
42. Boon K, Edwards JB, Siu IM et al: Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene, 2003; 22: 7687-7694 (Pubitemid 37464103)
43. Boon K, Edwards JB, Eberhart CG, Riggins GJ: Identification of astrocytoma associated genes including cell surface markers. BMC Cancer, 2004; 4: 39 (Pubitemid 40180247)
44. Boon K, Osorio EC, Greenhut SF et al: An anatomy of normal and malignant gene expression. Proc Natl Acad Sci USA, 2002; 99: 11287-11292 (Pubitemid 34920918)
45. Porter DA, Krop IE, Nasser S et al: A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res, 2001; 61: 5697-5702 (Pubitemid 32769079)
46. Krop IE, Sgroi D, Porter DA et al: HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells. Proc Natl Acad Sci USA, 2001; 98: 9796-9801 (Pubitemid 32769383)
47. Shipitsin M, Campbell LL, Argani P et al: Molecular definition of breast tumor heterogeneity. Cancer Cell, 2007; 11: 259-273 (Pubitemid 46349843)
48. Seth P, Porter D, Lahti-Domenici J et al: Cellular and molecular targets of estrogen in normal human breast tissue. Cancer Res, 2002; 62: 4540-4544 (Pubitemid 34898571)
49. Seth P, Krop I, Porter D, Polyak K: Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). Oncogene, 2002; 21: 836-843
50. Allinen M, Beroukhim R, Cai L et al: Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell, 2004; 6: 17-32 (Pubitemid 38903159)
51. Zhang L, Zhou W, Velculescu VE et al: Gene expression profiles in normal and cancer cells. Science, 1997; 276: 1268-1272 (Pubitemid 27227367)
52. Sawanyawisuth K, Wongkham C, Pairojkul C et al: Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma: potential for drug target. Acta Oncol, 2007; 46: 378-385 (Pubitemid 46625045)
53. Welle S, Bhatt K, Thornton CA: Inventory of high-abundance mRNAs in skeletal muscle of normal men. Genome Res, 1999; 9: 506-513 (Pubitemid 29267683)
54. Argani P, Rosty C, Reiter RE et al: Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res, 2001; 61: 4320-4324 (Pubitemid 32685751)
55. Hough CD, Sherman-Baust CA, Pizer ES et al: Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res, 2000; 60: 6281-6287
56. Bowes Rickman C, Ebright JN, Zavodni ZJ et al: Defining the human macula transcriptome and candidate retinal disease genes using EyeSAGE. Invest Ophthalmol Vis Sci, 2006; 47: 2305-2316
57. Weeraratna AT, Becker D, Carr KM et al: Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene, 2004; 23: 2264-2274 (Pubitemid 38482542)
58. Lal A, Peters H, St Croix B et al: Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst, 2001; 93: 1337-1343 (Pubitemid 32910575)
59. Cerutti JM, Delcelo R, Amadei MJ et al: A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest, 2004; 113: 1234-1242 (Pubitemid 38544109)
60. Waghray A, Feroze F, Schober MS et al: Identification of androgen-regulated genes in the prostate cancer cell line LNCaP by serial analysis of gene expression and proteomic analysis. Proteomics, 2001; 1: 1327-1338 (Pubitemid 33587888)
61. Georgantas RW III, Tanadve V, Malehorn M et al: Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res, 2004; 64: 4434-4441 (Pubitemid 38856914)
62. Takashima M, Kuramitsu Y, Yokoyama Y et al: Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus- related hepatocellular carcinoma. Proteomics, 2003; 3: 2487-2493 (Pubitemid 38010125)
63. Yokoyama Y, Kuramitsu Y, Takashima M et al: Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics, 2004; 4: 2111-2116 (Pubitemid 38880376)
64. Campa MJ, Wang MZ, Howard B et al: Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res, 2003; 63: 1652-1656 (Pubitemid 36373658)
65. Lim SO, Park SJ, Kim W et al: Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun, 2002; 291: 1031-1037
66. Mikuriya K, Kuramitsu Y, Ryozawa S et al: Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography- mass spectrometry/mass spectrometry. Int J Oncol, 2007; 30: 849-855
67. Li Z, Zhao X, Bai S et al: Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol Cell Proteomics, 2008; 7: 1810-1823
68. Qi YJ, He QY, Ma YF et al: Proteomic identification of malignant transformation- related proteins in esophageal squamous cell carcinoma. J Cell Biochem, 2008; 104: 1625-1635
69. Al-Ghoul M, Bruck TB, Lauer-Fields JL et al: Comparative proteomic analysis of matched primary and metastatic melanoma cell lines. J Proteome Res, 2008; 7: 4107-4118
70. Howard BA, Zheng Z, Campa MJ et al: Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer, 2004; 46: 313-323 (Pubitemid 39487306)
71. Howard BA, Furumai R, Campa MJ et al: Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res, 2005; 65: 8853-8860 (Pubitemid 41377374)
72. Yang H, Chen J, Yang J et al: Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal. Biochem Biophys Res Commun, 2007; 361: 763-767 (Pubitemid 47238044)
73. Chen S, Zhang M, Ma H et al: Oligo-microarray analysis reveals the role of cyclophilin A in drug resistance. Cancer Chemother Pharmacol, 2008; 61: 459-469 (Pubitemid 350275981)
74. Obama K, Ura K, Li M et al: Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology, 2005; 41: 1339-1348 (Pubitemid 40770287)
75. Wang AG, Yoon SY, Oh JH et al: Identification of intrahepatic cholangiocarcinoma related genes by comparison with normal liver tissues using expressed sequence tags. Biochem Biophys Res Commun, 2006; 345: 1022-1032
76. Li M, Zhai Q, Bharadwaj U et al: Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer, 2006; 106: 2284-2294 (Pubitemid 43673252)
77. Bane FT, Bannon JH, Pennington SR et al: The microtubule-targeting agents, PBOX-6 [pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy]- 6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine] and paclitaxel, induce nucleocytoplasmic redistribution of the peptidyl-prolyl isomerases, cyclophilin A and pin1, in malignant hematopoietic cells. J Pharmacol Exp Ther, 2009; 329: 38-47
78. Yeh ES, Means AR: PIN1, the cell cycle and cancer. Nat Rev Cancer, 2007; 7: 381-388
79. Kabbage M, Chahed K, Hamrita B et al: Protein alterations in infiltrating ductal carcinomas of the breast as detected by nonequilibrium pH gradient electrophoresis and mass spectrometry. J Biomed Biotechnol, 2008; 2008: 564127 (Pubitemid 352002771)
80. Tamesa MS, Kuramitsu Y, Fujimoto M et al: Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis. Electrophoresis, 2009; 30: 2168-2181
81. Zheng J, Koblinski JE, Dutson LV et al: Prolyl isomerase cyclophilin A regulation of Janus-activated kinase 2 and the progression of human breast cancer. Cancer Res, 2008; 68: 7769-7778
82. Calhoun CC, Lu YC, Song J, Chiu R: Knockdown endogenous CypA with siRNA in U2OS cells results in disruption of F-actin structure and alters tumor phenotype. Mol Cell Biochem, 2009; 320: 35-43
83. Jin ZG, Berk BC: Role of secreted oxidative stress-induced factors (SOXFs) in the pathogenesis of atherosclerosis. Arch Mal Coeur Vaiss, 2004; 97: 1256-1259
84. Catterall JB, Rowan AD, Sarsfield S et al: Development of a novel 2D proteomics approach for the identification of proteins secreted by primary chondrocytes after stimulation by IL-1 and oncostatin M. Rheumatology (Oxford), 2006; 45: 1101-1109 (Pubitemid 44542097)
85. Huang CM, Ananthaswamy HN, Barnes S et al: Mass spectrometric proteomics profiles of in vivo tumor secretomes: capillary ultrafiltration sampling of regressive tumor masses. Proteomics, 2006; 6: 6107-6116
86. Zhu C, Wang X, Deinum J et al: Cyclophilin A participates in the nuclear translocation of apoptosis-inducing factor in neurons after cerebral hypoxia-ischemia. J Exp Med, 2007; 204: 1741-1748 (Pubitemid 47236312)
87. Cande C, Vahsen N, Kouranti I et al: AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis. Oncogene, 2004; 23: 1514-1521 (Pubitemid 38406513)
88. Fillies T, Werkmeister R, van Diest PJ et al: HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer, 2005; 5: 84 (Pubitemid 41461049)
89. Semenza GL: Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol, 1999; 15: 551-578 (Pubitemid 32250386)
90. Carmeliet P, Dor Y, Herbert JM et al: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 1998; 394: 485-490 (Pubitemid 28373960)
91. Choi KJ, Piao YJ, Lim MJ et al: Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res, 2007; 67: 3654-3662 (Pubitemid 46762150)
92. Xu Q, Leiva MC, Fischkoff SA et al: Leukocyte chemotactic activity of cyclophilin. J Biol Chem, 1992; 267: 11968-11971
93. Allain F, Vanpouille C, Carpentier M et al: Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin-mediated adhesion of peripheral blood T lymphocytes to extracellular matrix. Proc Natl Acad Sci USA, 2002; 99: 2714-2719 (Pubitemid 34240526)
94. Khromykh LM, Kulikova NL, Anfalova TV et al: Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells. Cell Immunol, 2007; 249: 46-53
95. Cui Y, Mirkia K, Florence Fu YH et al: Interaction of the retinoblastoma gene product, RB, with cyclophilin A negatively affects cyclosporininhibited NFAT signaling. J Cell Biochem, 2002; 86: 630-641 (Pubitemid 34839965)
96. Song J, Lu YC, Yokoyama K et al: Cyclophilin A is required for retinoic acid-induced neuronal differentiation in p19 cells. J Biol Chem, 2004; 279: 24414-24419 (Pubitemid 38725304)
97. Capano M, Virji S, Crompton M: Cyclophilin-A is involved in excitotoxin- induced caspase activation in rat neuronal B50 cells. Biochem J, 2002; 363: 29-36 (Pubitemid 34280608)
98. Reddy PA, Atreya CD: Identification of simian cyclophilin A as a calreticulin- binding protein in yeast two-hybrid screen and demonstration of cyclophilin A interaction with calreticulin. Int J Biol Macromol, 1999; 25: 345-351
99. Demaurex N, Distelhorst C: Cell biology. Apoptosis - the calcium connection. Science, 2003; 300: 65-67
100. Lim M, Martinez T, Jablons D et al: Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett, 1998; 441: 88-92 (Pubitemid 29012378)
101. Yurchenko V, Constant S, Bukrinsky M: Dealing with the family: CD147 interactions with cyclophilins. Immunology, 2006; 117: 301-309
102. Maekawa M, Suzuki-Toyota F, Toyama Y et al: Stage-specific localization of basigin, a member of the immunoglobulin superfamily, during mouse spermatogenesis. Arch Histol Cytol, 1998; 61: 405-415 (Pubitemid 29081033)
103. Damsker JM, Bukrinsky MI, Constant SL: Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. J Leukoc Biol, 2007; 82: 613-618 (Pubitemid 47367153)
104. Brazin KN, Mallis RJ, Fulton D, BAndreotti AH: Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A. Proc Natl Acad Sci USA, 2002; 99: 1899-1904 (Pubitemid 34168986)
105. Bruns K, Fossen T, Wray V et al: Structural characterization of the HIV-1 Vpr N terminus: evidence of cis/trans-proline isomerism. J Biol Chem, 2003; 278: 43188-43201 (Pubitemid 37345938)
106. Nadeau K, Das A, Walsh CT: Hsp90 chaperonins possess ATPase activity and bind heat shock transcription factors and peptidyl prolyl isomerases. J Biol Chem, 1993; 268: 1479-1487 (Pubitemid 23019801)
107. Luban J: Absconding with the chaperone: essential cyclophilin-Gag interaction in HIV-1 virions. Cell, 1996; 87: 1157-1159
108. Lu YC, Song J, Cho HY et al: Cyclophilin a protects Peg3 from hypermethylation and inactive histone modification. J Biol Chem, 2006; 281: 39081-39087 (Pubitemid 46041867)
109. Syed F, Rycyzyn MA, Westgate L, Clevenger CV: A novel and functional interaction between cyclophilin A and prolactin receptor. Endocrine, 2003; 20: 83-90 (Pubitemid 36515191)
110. Clevenger CV, Furth PA, Hankinson SE, Schuler LA: The role of prolactin in mammary carcinoma. Endocr Rev, 2003; 24: 1-27
111. Hankinson SE, Willett WC, Michaud DS et al: Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst, 1999; 91: 629-634 (Pubitemid 29194050)
112. Rose-Hellekant TA, Arendt LM, Schroeder MD et al: Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice. Oncogene, 2003; 22: 4664-4674
113. O'Neal KD, Chari MV, McDonald CH et al: Multiple cis-trans conformers of the prolactin receptor proline-rich motif (PRM) peptide detected by reverse-phase HPLC, CD and NMR spectroscopy. Biochem J, 1996; 315 (Pt 3): 833-844
114. Brown RJ, Adams JJ, Pelekanos RA et al: Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol, 2005; 12: 814-821
115. Jauliac S, Lopez-Rodriguez C, Shaw LM et al: The role of NFAT transcription factors in integrin-mediated carcinoma invasion. Nat Cell Biol, 2002; 4: 540-544 (Pubitemid 34752442)
116. Rycyzyn MA, Clevenger CV: The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci USA, 2002; 99: 6790-6795
117. Rycyzyn MA, Reilly SC, O'Malley K, Clevenger CV: Role of cyclophilin B in prolactin signal transduction and nuclear retrotranslocation. Mol Endocrinol, 2000; 14: 1175-1186 (Pubitemid 32260479)
118. Buda A, Pignatelli M: Cytoskeletal network in colon cancer: from genes to clinical application. Int J Biochem Cell Biol, 2004; 36: 759-765 (Pubitemid 38299390)
119. Erickson JW, Cerione RA: Multiple roles for Cdc42 in cell regulation. Curr Opin Cell Biol, 2001; 13: 153-157
120. Higgs HN, Pollard TD: Regulation of actin filament network formation through ARP2/3 complex: activation by a diverse array of proteins. Annu Rev Biochem, 2001; 70: 649-676
121. Ma L, Rohatgi R, Kirschner MW: The Arp2/3 complex mediates actin polymerization induced by the small GTP-binding protein Cdc42. Proc Natl Acad Sci USA, 1998; 95: 15362-15367 (Pubitemid 29018704)
122. Park SJ, Suetsugu S, Takenawa T: Interaction of HSP90 to N-WASP leads to activation and protection from proteasome-dependent degradation. Embo J, 2005; 24: 1557-1570 (Pubitemid 40646446)
123. Pan H, Luo C, Li R et al: Cyclophilin A is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein A2, activation and nuclear translocation of ERK1/2, and chemotactic cell migration. J Biol Chem, 2008; 283: 623-637
124. Semba S, Huebner K: Protein expression profiling identifies cyclophilin A as a molecular target in Fhit-mediated tumor suppression. Mol Cancer Res, 2006; 4: 529-538 (Pubitemid 44341363)
125. Harding MW, Handschumacher RE: Cyclophilin, a primary molecular target for cyclosporine. Structural and functional implications. Transplantation, 1988; 46: 29S-35S
126. Holzman TF, Egan DA, Edalji R et al: Preliminary characterization of a cloned neutral isoelectric form of the human peptidyl prolyl isomerase cyclophilin. J Biol Chem, 1991; 266: 2474-2479
127. Wang MZ, Shetty JT, Howard BA et al: Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate. Anal Chem, 2004; 76: 4343-4348
128. Mikol V, Kallen J, Pflugl G, Walkinshaw MD: X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 A resolution. J Mol Biol, 1993; 234: 1119-1130 (Pubitemid 24027241)
129. Mogayzel PJ, Jr.Wagner TL: Cyclosporin and tacrolimus do not potentiate oxidative damage in pulmonary epithelial cells. Transpl Int, 2003; 16: 709-712
130. Eckstein LA, Van Quill KR, Bui SK et al: Cyclosporin a inhibits calcineurin/ nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells. Invest Ophthalmol Vis Sci, 2005; 46: 782-790
131. Ciechomska I, Legat M, Golab J et al: Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in in vitro and in vivo studies. Int J Cancer, 2005; 117: 59-67 (Pubitemid 41262760)
132. Borel JF, Feurer C, Gubler HU, Stahelin H: Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions, 1976; 6: 468-475
133. Borel JF, Feurer C, Magnee C, Stahelin H: Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology, 1977; 32: 1017-1025 (Pubitemid 8120594)
134. Gothel SF, Marahiel MA: Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci, 1999; 55: 423-436
135. Andre N, Roquelaure B, Conrath J: Molecular effects of cyclosporine and oncogenesis: a new model. Med Hypotheses, 2004; 63: 647-652 (Pubitemid 39485832)
136. Penn I: Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl, 1998; 147-158
137. Gaston RS: Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis, 2001; 38: S25-35
138. Penn I: Why do immunosuppressed patients develop cancer? Crit Rev Oncog, 1989; 1: 27-52
139. Sheil AG: Cancer in immune-suppressed organ transplant recipients: aetiology and evolution. Transplant Proc, 1998; 30: 2055-2057
140. Kelly GE, Meikle W, Sheil AG: Scheduled and unscheduled DNA synthesis in epidermal cells of hairless mice treated with immunosuppressive drugs and UVB-UVA irradiation. Br J Dermatol, 1987; 117: 429-440 (Pubitemid 18066482)
141. Ahlers C, Kreideweiss S, Nordheim A, Ruhlmann A: Cyclosporin A inhibits Ca2+-mediated upregulation of the DNA repair enzyme DNA polymerase beta in human peripheral blood mononuclear cells. Eur J Biochem, 1999; 264: 952-959 (Pubitemid 29437227)
142. Herman M, Weinstein T, Korzets A et al: Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med, 2001; 137: 14-20 (Pubitemid 32100171)
143. Vamvakas S, Bahner U, Becker P et al: Impairment of DNA repair in the course of long-term hemodialysis and under cyclosporine immunosuppression after renal transplantation. Transplant Proc, 1996; 28: 3468-3473 (Pubitemid 26415560)
144. Shin GT, Khanna A, Ding R et al: In vivo expression of transforming growth factor-beta1 in humans: stimulation by cyclosporine. Transplantation, 1998; 65: 313-318
145. Prashar Y, Khanna A, Sehajpal P et al: Stimulation of transforming growth factor-beta 1 transcription by cyclosporine. FEBS Lett, 1995; 358: 109-112
146. Beatty PR, Krams SM, Esquivel CO, Martinez OM: Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. Transplantation, 1998; 65: 1248-1255
147. Kong JY, Rabkin SW: Palmitate-induced apoptosis in cardiomyocytes is mediated through alterations in mitochondria: prevention by cyclosporin A. Biochim Biophys Acta, 2000; 1485: 45-55
148. Pritchard DE, Singh J, Carlisle DL, Patierno SR: Cyclosporin A inhibits chromium(VI)-induced apoptosis and mitochondrial cytochrome c release and restores clonogenic survival in CHO cells. Carcinogenesis, 2000; 21: 2027-2033 (Pubitemid 30843738)
149. Yerushalmi B, Dahl R, Devereaux MW et al: Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology, 2001; 33: 616-626 (Pubitemid 32185224)
150. 2-induced apoptosis of human fibroblasts. FEBS Lett, 1999; 447: 274-276
151. Stewart T, Tsai SC, Grayson H et al: Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet, 1995; 346: 796-798
152. Hansson MJ, Mattiasson G, Mansson R et al: The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria. J Bioenerg Biomembr, 2004; 36: 407-413 (Pubitemid 39619849)
153. Ptak RG, Gallay PA, Jochmans D et al: Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother, 2008; 52: 1302-1317
154. Ma S, Boerner JE, TiongYip C et al: NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother, 2006; 50: 2976-2982
155. Goto K, Watashi K, Murata T et al: Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem Biophys Res Commun, 2006; 343: 879-884
156. Inoue K, Umehara T, Ruegg UT et al: Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology, 2007; 45: 921-928 (Pubitemid 46631561)
157. Tiepolo T, Angelin A, Palma E et al: The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1 myopathic mice. Br J Pharmacol, 2009; 157(6): 1045-1052
158. Crabbe R, Vuagniaux G, Dumont JM et al: An evaluation of the cyclophilin
159. Mori T, Itami S, Yanagi T et al: Use of a real-time fluorescence monitoring system for high-throughput screening for prolyl isomerase inhibitors. J Biomol Screen, 2009; 14: 419-424
160. Daum S, Schumann M, Mathea S et al: Isoform-Specific Inhibition of Cyclophilins. Biochemistry, 2009; 48(26): 6268-6277
161. Hopper ED, Roulhac PL, Campa MJ et al: Throughput and efficiency of a mass spectrometry-based screening assay for protein-ligand binding detection. J Am Soc Mass Spectrom, 2008; 19: 1303-1311